Skip to main content

This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.

This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.

Adverse events reporting information can be found in the footer of this page.

Home
  • RLT Home
  • Introduction to RLT
  • Neuroendocrine tumours
  • Prostate cancer

Popular Search

  • prrt
  • masterclass
  • part
  • 2022
  • 2023

Recent News

Pluvicto Clinical Trials
LUTATHERA® (lutetium [177Lu] oxodotreotide) Safety Information
Coming soon
Search

You do not have an account yet? Register here.

Register with your e-mail address
Free specialist information, congresses, training opportunities and much more awaits you.

Register with E-mail

User login

Log in with your username and password

  • Forgot Password?
×

Ask Speakers

×

Medical Information Request

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of public.

Yes, I am a UK healthcare professional
No, I am a member of the public
Privacy policy
Cookie Settings
Terms of use
Site directory

Novartis Pharmaceuticals UK Limited is a limited liability company registered in England and Wales under number 119006.
Registered office: The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ

UK | February 2025 | FA-11281060

This page is intended for UK healthcare professionals and other relevant decision makers only.

This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.

©2025 Novartis Pharmaceuticals UK Limited. All rights reserved.